<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>12 Key PV Practice Requirements</title>
    <!-- Load Tailwind CSS -->
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- Load Inter Font -->
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700;800&display=swap" rel="stylesheet">
    <style>
        body {
            font-family: 'Inter', sans-serif;
            background-color: #f1f5f9; /* Light blue-gray background */
        }
        .header-bg {
            background-color: #1e3a8a; /* Dark blue primary color */
            border-bottom: 8px solid #06b6d4; /* Cyan accent */
        }
        .section-title {
            color: #1e3a8a;
            border-left: 6px solid #06b6d4;
        }
        .practice-item {
            background-color: white;
            transition: transform 0.2s ease-in-out;
        }
        .practice-item:hover {
            transform: translateY(-3px);
            box-shadow: 0 10px 15px rgba(0, 0, 0, 0.1);
        }
    </style>
</head>
<body>
    <div class="header-bg text-white p-6 md:p-10 rounded-b-xl shadow-lg mb-12">
        <div class="max-w-4xl mx-auto">
            <h1 class="text-4xl md:text-5xl font-extrabold mb-3 tracking-tight">
                The 12 PV Practice Pillars
            </h1>
            <p class="text-xl font-light opacity-90">
                Essential requirements for Pharmacovigilance compliance in the MENA region, focused on SFDA GVP standards.
            </p>
        </div>
    </div>

    <div class="max-w-4xl mx-auto px-4 pb-12">
        
        <div class="space-y-10">

            <!-- 1. Case Processing & Signal Detection -->
            <section>
                <h2 class="section-title text-2xl font-bold pl-4 py-1 mb-5 rounded-md">
                    1. Case Processing & Signal Detection (4 Requirements)
                </h2>
                <p class="text-gray-600 mb-6">
                    Focuses on the timely collection, processing, and proactive analysis of safety data from various sources.
                </p>
                <div class="grid grid-cols-1 md:grid-cols-2 gap-6">
                    <div class="practice-item p-5 rounded-xl shadow-md border-t-4 border-t-green-500">
                        <a href="https://ade.sfda.gov.sa/Request/AdeRequest" target="_blank" rel="noopener noreferrer" class="hover:underline">
                            <span class="text-lg font-bold text-green-700 block mb-2">1. ICSR Timeliness</span>
                        </a>
                        <p class="text-gray-700">All local Individual Case Safety Reports (ICSRS) are entered into the PV system within **SFDA-defined timelines**.</p>
                    </div>
                    <div class="practice-item p-5 rounded-xl shadow-md border-t-green-500 border-t-4">
                        <a href="https://www.sfda.gov.sa/ar/drugs-safety-labeling" target="_blank" rel="noopener noreferrer" class="hover:underline">
                            <span class="text-lg font-bold text-green-700 block mb-2">2. ADR Follow-up</span>
                        </a>
                        <p class="text-gray-700">Follow-ups for incomplete ADR reports are performed and documented according to **SFDA timelines**.</p>
                    </div>
                    <div class="practice-item p-5 rounded-xl shadow-md border-t-green-500 border-t-4">
                        <a href="https://sfda.gov.sa/en/higher-pharmacovigilance-advisory-committee-decisions" target="_blank" rel="noopener noreferrer" class="hover:underline">
                        <span class="text-lg font-bold text-green-700 block mb-2">3. Signal Review</span>
                        <p class="text-gray-700">Signal detection and review activities are conducted at the **frequency required** by SFDA GVP or internal SOPs.</p>
                    </div>
                    <div class="practice-item p-5 rounded-xl shadow-md border-t-green-500 border-t-4">
                        <span class="text-lg font-bold text-green-700 block mb-2">4. Literature Screening</span>
                        <p class="text-gray-700">Local scientific literature is screened for potential adverse events as required by **SFDA GVP**.</p>
                    </div>
                </div>
            </section>
            
            <!-- 2. Risk Management & Communication -->
            <section>
                <h2 class="section-title text-2xl font-bold pl-4 py-1 mb-5 rounded-md">
                    2. Risk Management & Communication (3 Requirements)
                </h2>
                <p class="text-gray-600 mb-6">
                    Details the required actions for assessing, documenting, and communicating established and emerging risks.
                </p>
                <div class="grid grid-cols-1 md:grid-cols-3 gap-6">
                    <div class="practice-item p-5 rounded-xl shadow-md border-t-orange-500 border-t-4">
                        <span class="text-lg font-bold text-orange-700 block mb-2">5. RMP Maintenance</span>
                        <p class="text-gray-700">When new safety information arises, the local **Risk Management Plan (RMP) is updated** and submitted to SFDA as required.</p>
                    </div>
                    <div class="practice-item p-5 rounded-xl shadow-md border-t-orange-500 border-t-4">
                        <span class="text-lg font-bold text-orange-700 block mb-2">6. RMM Execution</span>
                        <p class="text-gray-700">Direct Healthcare Professional Communications (DHPCs), patient cards, and other **RMMs are distributed and documented** according to the SFDA-approved plan.</p>
                    </div>
                    <div class="practice-item p-5 rounded-xl shadow-md border-t-orange-500 border-t-4">
                        <span class="text-lg font-bold text-orange-700 block mb-2">7. Safety Escalation</span>
                        <p class="text-gray-700">New or emerging safety information is **escalated to SFDA and company management** through a documented procedure.</p>
                    </div>
                </div>
            </section>

            <!-- 3. System & Quality Compliance -->
            <section>
                <h2 class="section-title text-2xl font-bold pl-4 py-1 mb-5 rounded-md">
                    3. System & Quality Compliance (3 Requirements)
                </h2>
                <p class="text-gray-600 mb-6">
                    Covers the mandatory documentation and maintenance of the PV system's quality standards for auditing.
                </p>
                <div class="grid grid-cols-1 md:grid-cols-3 gap-6">
                    <div class="practice-item p-5 rounded-xl shadow-md border-t-cyan-500 border-t-4">
                        <span class="text-lg font-bold text-cyan-700 block mb-2">8. PSMF/PSSF Readiness</span>
                        <p class="text-gray-700">A local **PSMF / PSSF is maintained, complete, and kept up to date** for SFDA inspection.</p>
                    </div>
                    <div class="practice-item p-5 rounded-xl shadow-md border-t-cyan-500 border-t-4">
                        <span class="text-lg font-bold text-cyan-700 block mb-2">9. SOP Recertification</span>
                        <p class="text-gray-700">PV procedures (SOPs / WIs) are **reviewed and updated regularly** to ensure continued SFDA compliance.</p>
                    </div>
                    <div class="practice-item p-5 rounded-xl shadow-md border-t-cyan-500 border-t-4">
                        <span class="text-lg font-bold text-cyan-700 block mb-2">10. CAPA Implementation</span>
                        <p class="text-gray-700">Corrective and Preventive Actions (**CAPAs**) from SFDA inspections or audits are **implemented and closed within the agreed timelines**.</p>
                    </div>
                </div>
            </section>
            
            <!-- 4. Oversight & Personnel -->
            <section>
                <h2 class="section-title text-2xl font-bold pl-4 py-1 mb-5 rounded-md">
                    4. Oversight & Personnel (2 Requirements)
                </h2>
                <p class="text-gray-600 mb-6">
                    Ensuring all personnel are qualified and external partners are properly monitored.
                </p>
                <div class="grid grid-cols-1 md:grid-cols-2 gap-6">
                    <div class="practice-item p-5 rounded-xl shadow-md border-t-indigo-500 border-t-4">
                        <span class="text-lg font-bold text-indigo-700 block mb-2">11. Third-Party Control</span>
                        <p class="text-gray-700">PV activities performed by distributors or third-party providers are **overseen through audits, metrics, or compliance reviews**.</p>
                    </div>
                    <div class="practice-item p-5 rounded-xl shadow-md border-t-indigo-500 border-t-4">
                        <span class="text-lg font-bold text-indigo-700 block mb-2">12. Employee Training</span>
                        <p class="text-gray-700">New employees receive **PV induction training within 30 days of joining**, as required by SFDA GVP.</p>
                    </div>
                </div>
            </section>
            
        </div>
        
    </div>
    
    <footer class="text-center p-6 mt-12 text-gray-500 border-t border-gray-300">
        <p class="text-sm">Reference Document based on Pharmacovigilance Professional Survey (Practice Section).</p>
        <p class="text-xs mt-1">Acronyms: SFDA (Saudi Food and Drug Authority), GVP (Good Pharmacovigilance Practices), ICSR (Individual Case Safety Report), RMP (Risk Management Plan), RMM (Risk-Minimization Measure), PSMF (PV System Master File), CAPA (Corrective and Preventive Action).</p>
    </footer>
</body>
</html>

